Atea Pharmaceuticals (AVIR) Competitors $3.47 -0.17 (-4.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.48 +0.00 (+0.14%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. HROW, WVE, CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, and DYNShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Harrow (HROW), WAVE Life Sciences (WVE), Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Harrow WAVE Life Sciences Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Harrow (NASDAQ:HROW) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend HROW or AVIR? Harrow presently has a consensus price target of $63.83, suggesting a potential upside of 104.40%. Atea Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 72.91%. Given Harrow's stronger consensus rating and higher probable upside, research analysts plainly believe Harrow is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation & earnings, HROW or AVIR? Harrow has higher revenue and earnings than Atea Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M5.74-$17.48M-$0.56-55.77Atea PharmaceuticalsN/AN/A-$168.38M-$1.65-2.10 Which has more risk & volatility, HROW or AVIR? Harrow has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Is HROW or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% Atea Pharmaceuticals N/A -31.26%-29.27% Does the media prefer HROW or AVIR? In the previous week, Harrow had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Harrow and 2 mentions for Atea Pharmaceuticals. Harrow's average media sentiment score of 0.41 beat Atea Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of HROW or AVIR? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 15.2% of Harrow shares are owned by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryHarrow beats Atea Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$311.51M$3.00B$5.47B$9.53BDividend YieldN/A2.43%4.74%4.08%P/E Ratio-2.1017.6228.6723.80Price / SalesN/A268.97422.2688.08Price / CashN/A41.9535.4557.96Price / Book0.678.508.275.55Net Income-$168.38M-$55.06M$3.24B$259.03M7 Day Performance-11.03%-3.98%-3.63%-4.56%1 Month Performance-4.41%9.59%4.40%4.49%1 Year Performance0.58%6.72%25.97%18.05% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals1.6726 of 5 stars$3.47-4.7%$6.00+72.9%-4.4%$311.51MN/A-2.1070News CoverageUpcoming EarningsHROWHarrow2.5019 of 5 stars$34.86-3.7%$63.83+83.1%+27.2%$1.33B$212.86M-62.25180Upcoming EarningsWVEWAVE Life Sciences4.7417 of 5 stars$8.18-2.6%$20.43+149.7%+40.1%$1.31B$108.30M-9.74240News CoverageEarnings ReportAnalyst ForecastCDTXCidara Therapeutics3.1262 of 5 stars$62.68+1.3%$57.29-8.6%+389.1%$1.25B$1.27M-2.1390Upcoming EarningsCVACCureVac3.578 of 5 stars$5.42-0.7%$6.83+26.1%+51.1%$1.22B$579.18M5.89880AUPHAurinia Pharmaceuticals2.319 of 5 stars$8.89-0.4%$11.50+29.4%+87.0%$1.21B$235.13M31.75300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionPRAXPraxis Precision Medicines2.4074 of 5 stars$55.65-6.0%$94.11+69.1%-5.0%$1.21B$8.55M-5.19110Analyst ForecastCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.117 of 5 stars$28.92-0.9%$24.40-15.6%+41.1%$1.18B$1.02B37.081,940Positive NewsDividend AnnouncementSRPTSarepta Therapeutics4.7 of 5 stars$13.86+16.2%$51.42+271.0%-89.0%$1.17B$1.90B-5.151,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeDYNDyne Therapeutics3.572 of 5 stars$9.31-6.4%$40.63+336.4%-76.1%$1.13BN/A-2.59100Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Harrow Alternatives WAVE Life Sciences Alternatives Cidara Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Sarepta Therapeutics Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
